Treating paediatric acrodermatitis continua of Hallopeau with adalimumab: a case series
- 24 September 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (1) , 195-196
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Biologics in the treatment of pustular psoriasisExpert Opinion on Drug Safety, 2020
- Three cases of IL36RN-associated pustulosis: An evolution of acrodermatitis continua of Hallopeau to generalized pustular psoriasisIndian Journal of Dermatology, Venereology and Leprology, 2020
- Biological therapy for pustular psoriasis: a systematic reviewInternational Journal of Dermatology, 2019
- Adalimumab in severe plaque psoriasis of childhood: A multi‐center, retrospective real‐life study up to 52 weeks observationDermatologic Therapy, 2019
- Acrodermatitis continua of Hallopeau: clinical perspectivesPsoriasis: Targets and Therapy, 2019
- Clinical and genetic differences between pustular psoriasis subtypesJournal of Allergy and Clinical Immunology, 2019
- Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label studyThe Journal of Dermatology, 2018
- European consensus statement on phenotypes of pustular psoriasisJournal of the European Academy of Dermatology and Venereology, 2017